Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes (NCT06334133)

🧪 Interventions in This Study

• Cadisegliatin 800 mg QD (DRUG)
• Cadisegliatin 800 mg BID (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (52 Sites)

Showing the first 25 of 52 sites.

• Scottsdale Clinical Trials — Scottsdale, Arizona
• Baptist Health Center for Clinical Research — Little Rock, Arkansas
• Amicis Research Center — Granada Hills, California
• AME Clinical Research — Huntington Beach, California
• 310 Clinical Research — Inglewood, California
• Scripps Whittier Diabetes Institute — La Jolla, California
• IMAX Clinical Trials — La Palma, California
• Paradigm Clinical Research - Modesto — Modesto, California
• Paradigm Clinical Research Centers LLC — San Diego, California
• Acclaim Clinical Research — San Diego, California
• The Lundquist Institute — Torrance, California
• Focus Clinical Research — West Hills, California
• Denver Endocrinology Diabetes and Thyroid Center — Englewood, Colorado
• BayCare Health Systems — Clearwater, Florida
• Metabolic Research Institute, Inc — West Palm Beach, Florida
• Atlanta Diabetes Associates — Atlanta, Georgia
• Centricity Research - Columbus — Columbus, Georgia
• The Jones Center Clinical Research, LLC — Macon, Georgia
• Paradigm Clinical Research — Boise, Idaho
• DM Clinical Research — Indianapolis, Indiana
• Accellacare - McFarland — Ames, Iowa
• Iowa Diabetes and Endocrinology Research Center — West Des Moines, Iowa
• Johnson County Clin-Trials, LLC — Lenexa, Kansas
• MedStar Good Samaritan Hospital — Baltimore, Maryland
• Massachusetts General Hospital Diabetes Research Center — Boston, Massachusetts

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Diabetes Mellitus, Type 1

• Testing an Integrated Care Model Trial — Atlanta, Georgia
• Safety of ENC-201-CED ENCRT — Toronto, Ontario
• Teplizumab in Pediatric Stage 2 Type 1 Diabetes — San Francisco, California
• Allogenic Islet Cell Transplantation — Chicago, Illinois
• Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells — Charleston, South Carolina
• Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes — Stanford, California

Explore by condition: All Diabetes Mellitus, Type 1 clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.